These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36864566)

  • 1. eIg-based bispecific T-cell engagers targeting EGFR: Format matters.
    Kühl L; Schäfer AK; Kraft S; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2023; 15(1):2183540. PubMed ID: 36864566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
    Aschmoneit N; Kühl L; Seifert O; Kontermann RE
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The eIg technology to generate Ig-like bispecific antibodies.
    Kühl L; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of T-cell engagers selective for cells co-expressing two antigens.
    Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
    MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
    Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release.
    Schardt JS; Walseng E; Le K; Yang C; Shah P; Fu Y; Alam K; Kelton CR; Gu Y; Huang F; Lin J; Liu W; Dippel A; Zhang H; Mulgrew K; Pryts S; Chennupati V; Chen HC; Denham J; Chen X; Pradhan P; Wu Y; Hardman C; Zhao C; Kierny M; Song Y; Dovedi SJ; Cemerski S; Mazor Y
    MAbs; 2024; 16(1):2395499. PubMed ID: 39205483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells.
    Aschmoneit N; Steinlein S; Kühl L; Seifert O; Kontermann RE
    Sci Rep; 2021 Jul; 11(1):13880. PubMed ID: 34230555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
    Yoneyama T; Kim MS; Piatkov K; Wang H; Zhu AZX
    PLoS Comput Biol; 2022 Jul; 18(7):e1009715. PubMed ID: 35839267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific T-cell engagers for treatment of multiple myeloma.
    Ravi G; Costa LJ
    Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy.
    McCue AC; Demarest SJ; Froning KJ; Hickey MJ; Antonysamy S; Kuhlman B
    MAbs; 2024; 16(1):2373325. PubMed ID: 38962811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies.
    Mohan N; Ayinde S; Peng H; Dutta S; Shen Y; Falkowski VM; Biel TG; Ju T; Wu WJ
    Front Immunol; 2024; 15():1376096. PubMed ID: 38863707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.
    Leclercq G; Haegel H; Schneider A; Giusti AM; Marrer-Berger E; Boetsch C; Walz AC; Pulko V; Sam J; Challier J; Ferlini C; Odermatt A; Umaña P; Bacac M; Klein C
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
    Mølgaard K; Harwood SL; Compte M; Merino N; Bonet J; Alvarez-Cienfuegos A; Mikkelsen K; Nuñez-Prado N; Alvarez-Mendez A; Sanz L; Blanco FJ; Alvarez-Vallina L
    Cancer Immunol Immunother; 2018 Aug; 67(8):1251-1260. PubMed ID: 29869168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
    Baeuerle PA; Wesche H
    Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers.
    Wang N; Patel H; Schneider IC; Kai X; Varshney AK; Zhou L
    Antib Ther; 2021 Apr; 4(2):90-100. PubMed ID: 34169228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
    Trinklein ND; Pham D; Schellenberger U; Buelow B; Boudreau A; Choudhry P; Clarke SC; Dang K; Harris KE; Iyer S; Jorgensen B; Pratap PP; Rangaswamy US; Ugamraj HS; Vafa O; Wiita AP; van Schooten W; Buelow R; Force Aldred S
    MAbs; 2019; 11(4):639-652. PubMed ID: 30698484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.